global-women-health-orthopedics-congress-2018-posters

6 / 22

Page 38
S e p t e m b e r 0 6 - 0 7 , 2 0 1 8 | B a n g k o k , T h a i l a n d
Note:
alliedacademies Joint Event on
Global Women Health 2018 & Orthopedics Congress 2018 Archives of General Internal Medicine | ISSN: 2591-7951 | Volume 2
BREAST CANCER, GYNECOLOGY AND WOMEN HEALTH
ORTHOPEDICS AND RHEUMATOLOGY
&
World Congress on
Annual Conference on
Nur Indah Purnamasari et al., Arch Gen Intern Med 2018, Volume 2 | DOI: 10.4066/2591-7951-C3-009
EVALUATION OF SEVERE PREECLAMPSIA
CLINICAL PATHWAYS IMPLEMENTATION
BASED ON LENGTH OF STAY, USE OF
DIAGNOSTIC TESTS AND USE OF DRUGS
INDICATORS AT WAHIDIN SUDIROHUSODO
HOSPITAL
Nur Indah Purnamasari and Isharyah Sunarno
Hasanuddin University, Indonesia
Background:The purposes of clinical pathways are reducing variations within
health care, more predictable cost, more standardized cares, improving
quality of care, improving the procedure costs, improving the quality of
collected information and as a counter-check especially in high cost and high
value cases.
Method: A prospective cohort study was used to compare evaluation of
clinical pathways implementation in patients with severe preeclampsia.
Statistical analysis using Kolmogorov-Smirnov test and Mann Whitney U test.
Result: More patients with three days length of stay (10 patients or 50%)
while patients without clinical pathways implementation with three days
length of stay were (four patients or 20%). Type of test done in patients with
clinical pathways implementation was complete blood count (20 patients or
100%) and the least was cardiotocography (eight patients or 40%). The most
common drug used in patients with clinical pathways implementation was
nifedipine/perdipine (19 patients or 95%) and the least was methyldopa (two
patients or 10%)
Conclusion: Clinical pathways implementation in patients with severe
preeclampsia may reduce length of stay in hospital, provide guidelines for
appropriate diagnostic test, but there is no difference in the effectiveness of
drug use.
Nur Indah Purnamasari has completed her doctor’s
education program in the Medical Faculty of Indone-
sian Muslim Universities. Currently, she is undergoing
an obstetrics and gynecology specialist medical edu-
cation program at Hasanuddin University.
BIOGRAPHY